anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
1. An isolated pseudomycin of general formula wherein Y is a radical or a pharmaceutically acceptable salt, hydrate or ester thereof. 2. The pseudomycin of claim 1, comprising pseudomycin A&#39; having the formula a pharmaceutically acceptable salt, hydrate or ester thereof. 3. The pseudomycin of claim 1, comprising pseudomycin B&#39; having the formula a pharmaceutically acceptable salt, hydrate or ester thereof. 4. A method of inhibiting fungal activity comprising contacting a fungus with an isolated pseudomycin natural product comprising a pseudomycin A&#39;, a pseudomycin B&#39;, a mixture thereof, or a pharmaceutically acceptable salt, hydrate or ester thereof. 5. A method of reducing the symptoms of a fungal infection in a patient in need thereof comprising administering to the patient an effective amount of a composition comprising an isolated pseudomycin natural product comprising a pseudomycin A&#39;, a pseudomycin B&#39;, a mixture thereof, or a pharmaceutically acceptable salt, hydrate or ester thereof of claim 1. 6. The use of the compounds of Claim 1 in the manufacture of a pharmaceutical composition for inhibiting fungal activity. 7. The use of the compounds of Claim 1 in the manufacture of a pharmaceutical composition for inhibiting fungal activity or reducing the symptoms of a fungal infection in a patient. 8. A method of fungus inhibiting in or on a plant comprising contacting said plant with an isolated pseudomycin of claim 1 selected from the pseudomycin A&#39; of the formula or from the pseudomycin B&#39; of the formula or a pharmaceutically acceptable salt, hydrate or ester thereof.
A veterinary composition for the treatment of infestations of nematodes in sheep and cattle by oral or parenteral administration comprises 100 parts by weight of one or more ammonium cations of the formula &lt;FORM:0973231/A5-A6/1&gt; wherein R1 is a hydrogen or halogen atom or a methyl, ethyl, methoxy, methyl-mercapto, formyl, acetyl, cyano, nitro or nitroso group, when M is a benzyl group optionally substituted in the ortho-position with a halogen atom or a methyl, ethyl, methoxy, methyl mercapto, nitro or nitroso group or R1 is a hydrogen or halogen atom or a methyl or nitro group when M is a thenyl group, in the form of one or more of their pharmaceutically acceptable salts and 0.05 to 25.0 parts by weight of one or more esters of formula &lt;FORM:0973231/A5-A6/2&gt; wherein R2 and R3 are the same or different and each is an alkyl group, X is oxygen or sulphur and R4 is hydrogen or halogen.  Preferably both R2 and R3 are ethyl. Specified esters are 3 - chloro - 4 - methyl - 7 - oxycoumarin - o,o - diethylphosphoric acid ester and the corresponding thiophosphoric acid ester, 4-methyl-7 - oxycoumarin - o,o - diethylphosphoric acid ester and 3-bromo-4-methyl-7-oxycoumarin-o,o-diethyl thiophosphoric acid ester.  Preferred salts of Formula I are the chloride, bromide, iodide, citrate, p-toluenesulphonate p - chlorobenzenesulphonate, 2 - hydroxy - 3, naphthoate and embonate.  The composition may be administered orally, as non-aqueous suspensions, powders, tablets, capsules, cachets, granules, animal feedstuffs, emulsions of the oil-in-water or water-in-oil type, syrups, drenches, coated tablets or granules, aqueous or oil suspensions and dispersible powders.  The compositions are formulated with diluents, anionic surface-active agents, dispersing agents, lubricants, flavours, thickeners, preservatives and binders.
Preparation of polyhalogens ethers of formula RO-(C2H3(CH2X)O)-n H where R is 8-22C aliphatic radical, n is &gt;2 10 and x is a halogen atom by polycondensing glycerol epichlorohydrin onto a compd ROH in molar ratio n:1 in the presence of BF3 or SbCl5 as catalyst, where R is as defined above and n is less than 10. R is stearyl, oleyl, tetradecyl, lauryl, catyl or monylphenyl. Polycondensation is carried out at 25-160 deg.C esp. 60-120 deg.C. Intermediates in the prepn. of surface active agents useful as emulsifiers, foaming agents, wetting agents etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide new functional drinking water using deep sea water which has mineral ingredients approximately same with those of human bodies.  &lt;P&gt;SOLUTION: Provided is the new functional drinking water characterized by mixing mineral-containing water 1 with slightly digestible dextrin 7 to mainly contribute to the stabilization of blood glucose level. The mineral-containing water is at least one of land-based natural water 3 and desalted deep water 2 separated from deep sea water M in a depth of ≥200 m under sea level. The land-based natural water is drawn up from the underground, and the deep sea water is Japan sea-characteristic cold water N collected from Toyama bay. The desalted deep water is mineral-concentrated water n3 of the Japan sea-characteristic cold water separated by a multistage type electrodialysis method, and the slightly digestible dextrin is at least one of reduced type dextrin 5 and a non-reduced type dextrin 6.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
FIELD: medicine, pediatrics, neurology, psychiatry.SUBSTANCE: invention relates to medicine, namely to pediatrics, neurology, psychiatry. On the day of admission of the patient to the medical rehabilitation department, a psychiatrist conducts a consultation to determine the mental status, according to the result of which drug therapy is prescribed. Further, the patient is consulted by a neurologist, determines the neurological status and prescribes drug therapy. Then the patient undergoes examination by a psychologist using diagnostic tests and diagnostic techniques. From the next day of the child&#39;s stay in the department, the psychologist conducts daily psycho-correction using game therapy, body-oriented therapy, dance therapy, art therapy. Next, the child is examined by a speech therapist-defectologist with the appointment of daily classes. After all the above examinations, on the day of admission, the physical therapy doctor prescribes a course of physiotherapy exercises, which includes daily group sessions, followed by a transition to mechanotherapy using simulators. Physiotherapist prescribes massage of the neck and collar zone, electrosonic therapy, electrophoresis of 2% Ca and 2% Br according to Vermel and Shcherbak. The reflexologist prescribes a course according to the &#34;U-sin&#34; acupuncture method.EFFECT: provides stabilization of the emotional sphere, normalization of behavioral reactions, cognitive and emotional functions of the child due to the ongoing comprehensive rehabilitation measures for children and adolescents with behavioral and emotional disorders, suffering from mental disorders.1 cl, 3 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a means for improving newly required qualities such as the colorless transparency of coating films themselves and the dispersion stability of the pearl gloss agent in a nail cosmetic which contains a pearl gloss agent.  &lt;P&gt;SOLUTION: This nail cosmetic comprising nitrocellulose and an alkyd resin is characterized by containing the pearl gloss agent and octocrylene. The content of the nitrocellulose is preferably 1 to 20 mass%, and the alkyd resin is preferably 1 to 15 mass%. The content of the octocrylene is preferably 0.1 to 5 mass%. It is preferable to contain small laminated resin pieces as the pearl gloss agent.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for using a sugar acid to inhibit, retard growth and/or viability of plant pathogens, e.g., prokaryotes, eukaryotes and the like, infecting to a plant or a part of the plant or ectoparasitic by other means, or to control them by other means.  &lt;P&gt;SOLUTION: The method is to prevent or treat infection caused by a range of fungal pathogens in animals, plants or stored plant products and includes a process for administering an effective amount of the sugar acid, above all, mannoic acid, gluconic acid or galacturonic acid. The sugar acid can be delivered by a biocontroller that can produce the sugar acid. The biocontroller is, e.g., Pseudomonas strain AN5. The strain is characterized by the capacity to convert an aldose to a sugar acid. Nucleotide sequences from a group of enzymes in the Pseudomonas PQQ enzyme pathway which may be used to transform microorganisms and plants so that they produce the sugar acids at levels sufficient to control the growth or viability of the pathogens are also disclosed.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PCT No. PCT/RO96/00003 Sec. 371 Date Oct. 3, 1997 Sec. 102(e) Date Oct. 3, 1997 PCT Filed Mar. 14, 1996 PCT Pub. No. WO96/32117 PCT Pub. Date Oct. 19, 1996This bioactive concentrate is an active substance-aqueous solution or lyophilized powder-consisting of anti-hyaluronidase and antiinflammatory mucopolysaccharide polymers and an addition of restitutive and anti-hyaluronidase chondroitinsulphate, which has a pH=4-6 and antihyaluronidase activity. The bioactive concentrate producing method consists in a two-phased treatment of animal-originated connective cartilaginous tissues such as bovine and sheep trachea, umbilical cord, young animal tendons, bowels, testicles or sea organisms, with phenol solution and the solution resulted is concentrated by vacuum evaporation and then defatted; after filtering, the supernatant obtained is treated for deproteinization, the ion excess is removed by passing through ion exchanger column, the alcohol solution is concentrated to remove alcohol until reaching a volume of 70% as against the aqueous solution subject to proteinzation. Drug compsitions contain the bioactive concentrate-solution or in lyophilized state-associated with synergic substances such as: heparin, sodium or lysin acetylsallicylate, ascorbic acid, vitamin E,&#34;I&#34;-like structured water, benzyl alcohol, propylene glycocou, plant extracts (Achillea, Calendula, Matricaria, Plantago, Hypericum) and usual excipients, being conditioned in the form of intramuscular or intraarticular injections, ointment, gel and suppositories. Finally the histamines are removed and chondroitin sulphate is added up to the concentration required.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a CD8T cell activation-inhibiting agent, and a therapeutic agent for rheumatism and a DNA vaccine for treating rheumatism.  &lt;P&gt;SOLUTION: The CD8T cell activation-inhibiting agent comprises a Jagged 1 gene or a Jagged 1 protein. The CD8T cell activation-inhibiting agent inhibits activation of a CD8T cell and accordingly makes prevention or treatment of rheumatism possible. Preferably, the gene above is particularly a structural gene in an extracellular region of the Jagged 1 protein. Preferably, a recombinant vector having the structural gene inserted therein is used as the DNA vaccine.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
A parasiticidal formulation is provided. This formulation includes a pyrrolidone solvent, a bridging solvent, and an parasiticidal agent. One or more parasiticidal agents may be included in the formulation. Preferably, the formulation contains both closantel and ivermectin. Another aspect of the present invention is a method of making this parasiticidal formulation. This method includes mixing a pyrrolidone solvent and a bridging solvent to form a solvent solution and adding one or more parasiticidal agents to the solvent solution. A further aspect of the present invention is a method for administering the parasiticidal formulation of the present invention to an animal. This method of administration includes providing the parasiticidal formulation described above and applying this formulation to the skin of an animal, wherein the formulation is absorbed through the animal&#39;s skin.
Cyclen-based chelates can be used as contrast agents for multi-modal imaging of tissue cells. The cyclen-based chelates are preferably polyazamacrocyclic molecules formed from 1,4,7,10, tetraazacyclododecane (&#34;cyclen&#34;) having varying chelating ions, phosphoester chains, and light harvesting moieties. By changing the chelating ion, phosphoester chain length and/or the light harvesting moiety different imaging techniques, such as MRI, CT, fluorescence and absorption, x-ray and NIR, may be employed to image the tissue cells. Additionally, the cyclen-based chelates may be conjugated to provide for site-specific delivery of the cyclen-based chelate to the desired tissue cells. The cyclen-based chelates may also be delivered to the tissue cells by attaching the cyclen-based chelates to a polymeric delivery vehicle. Although these cyclen-based chelates have a wide variety of application, the preferred use is for imaging of cancers cells, such as brain cancer, for improving resection of a cancerous tissue.
PURPOSE:To obtain a novel optically active decadiyn derivative enabling production by chemical synthesis of optically active 4,6-decadiyn-1,3,8-triol useful as an intermediate for various kind of medicines, agricultural chemicals, etc. CONSTITUTION:A compound expressed by formula I (R11 and R12 are halogen or protected OH; steric configuration of chiral centered carbon atom having water each independently adapts either one configuration in S-configuration and R-configuration), e.g. (3S, 8S)-1,10-di(tert. butyldimethylsilyloxy)-4,6- decadiyn-3,8-diol. The above-mentioned compound can be produced from a novel substance expressed by formula II (R3 is protected OH; A and B are H or direct bond together) through novel substances expressed by formula III and formula TV (R4 is OH, halogen, etc.; R4 is OH, R3, etc.) in 11 processes. Chiral natural substance (3S, 8S) can be produced in high purity of &gt;=90% via the above-mentioned method and optically active substance which does not exist in nature can be also produced in high purity.
PROBLEM TO BE SOLVED: To use a raw attenuated bacterium belonging to the species Streptococcus equi for the production of a vaccine for whole body administration against the infection of Streptococcus equi. SOLUTION: The raw attenuated bacterium belonging to the species Streptococcus equi is used for the production of a vaccine for whole body administration against the infection of the Streptococcus equi. Intramuscular administration into the muscles of necks, hind legs, fore legs or the like, submucous administration into mucosas such as lips, or the like, are preferable as the whole body administration. The bacterium is preferably Streptococcus equi TW 928 deposited as No. CBS 813.95. The vaccine is preferably administered at a dose of 10&lt;3&gt; to 10&lt;10&gt; . The vaccine is preferably prepared in the form of a lyophilized product. The administration of the vaccine into a whole body gives a substantially perfect protection against strangles differently from conventional intra-nasal administrations lack in perfection.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an isoquinoline alkaloid derivative slight in side effects and having high lipolytic action, and to provide a food preparation, a cosmetic and an antiobestic agent each made therefrom.  &lt;P&gt;SOLUTION: The isoquinoline alkaloid derivative having lipolytic action is a derivative where an isoquinoline alkaloid is bound to either one of caprylic acid, palmitic acid, eicosapentaenoic acid, docosahexaenoic acid, docosapentaenoic acid, α-lipoic acid, γ-linolenic acid, stearic acid, methylstearic acid, laurylic acid and 14-methylpalmitic acid. This derivative is obtained by adding a lipase for use in transesterification to pulverized lotus fruit followed by heating, or by fermenting fishes and soybeans with bacillus natto, and then making an extraction with vegetable oil. The food preparation or cosmetic comprises the isoquinoline alkaloid derivative, chrysanthemum flower extract-containing vegetable oil and pine needle extract-containing vegetable oil. The antiobestic agent comprises the isoquinoline alkaloid derivative.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a new nucleic acid/chitosan complex high in content of nucleic acid, strong in bondability, excellent in safety, usable as a research material for biochemistry, molecular biology, etc. SOLUTION: This water-insoluble nucleic acid/chitosan complex is obtained by bonding of a nucleic acid and precipitation from an aqueous solution of chitosan adjusted to pH about 5, such as a DNA/chitosan. The complex is prepared as a precipitate by mixing the aqueous solution of chitosan adjusted to pH about 5 with an aqueous solution of chitosan. The prepared nucleic acid/ chitosan complex has &gt;=10%(w/w) nucleic acid content, to be concrete, about 30-50%(w/w). The complex is stable in an organic solvent. The complex is usable for extraction, separation and purification of nucleic acid and purification of protein, etc.
An improved vector upon introduction into a suitable host containing the thermolabile repressor CI renders the host capable of effecting expression of a desired gene. The vector is a double-stranded DNA molecule which includes in 5&#39; to 3&#39; order the following: the promoter and operator PLOL from lambda bacteriophage; the N utilization site; a first restriction enzyme site permitting replacement of the ribosomal binding site which follows thereafter; a ribosomal bindig site; an ATG initiation codon or DNA which is converted into an ATG initiation codon upon insertion of the desired gene into the vector; a second restriction enzyme site for inserting the gene in phase with the ATG codon; a T1T2 rRNA transcription termination sequence; an origin of replication; and a fragment designated CI434 on which is included the gene for the repressor protein and its associated promoter and operator. Additionally, the vector may include a gene associated with a selectable or identifiable phenotypic trait which is manifested when the vector is present in the host. The distance between the 3&#39; end of PLOL and the 5&#39; end of the N utilization site is less than about 80 base pairs. The distance between the 3&#39; end of the N utilization site and the 5&#39; end of the ribosomal binding site is less than about 300 base pairs. Plasmids have been constructed from the vectors and used to produce bovine growth hormones.
NEW MATERIAL:A compound (salt) expressed by formulas I -IV (R&lt;4&gt; is H or protecting group of mercapto). USE:An antigen for analyzing hepatitis B viruses and antigen for hepatitis B vaccines. PREPARATION:For example, amino acids having amino group protected with tert-butoxycarbonyl group are successively condensed with a chloromethylated styrene-divinylbenzene copolymer resin as a carrier according to the amino acid sequence of the aimed peptide, and protecting groups are removed. The above- mentioned operation is repeated successively to give a peptide resin, which is then treated with hydrogen fluoride in the presence of a solvent to separate the resultant peptide from the carrier. Mercuric acetate and acetic acid are if necessary added thereto to adjust pH to 4, and hydrogen sulfide gas is blown thereinto under agitation to reduce the peptide and form an intramolecular cystine type peptide. Thus, the aimed peptide expressed by formulas I -IV is obtained.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a high safety composition for diet derived from a raw coffee bean by which superior diet effect can be obtained, and which is useful for prevention and treatment of life cycle-related diseases such as diabetes.  &lt;P&gt;SOLUTION: The composition for diet of the invention is characterised by containing a polar solvent extract of a degreased coffee bean as an effective component. The polar solvent extract is preferably a hydrous ethanol extract, more preferably a hydrous ethanol extract with a 40-90% (wt/wt) ethanol. The degreased raw coffee bean is preferably a raw coffee bean of which the oil component is extracted and separated with N-hexane. The composition for diet of the invention is preferably combindedly used together with any one kind or more kinds of Salacia extract, Oensothera tetraptera extract, Sesamin and Galcinia. The composition for diet of the invention can be used as a raw material for food and drink, medicine, or dermal outer-use agent.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To prepare compressed powdery cosmetics having smooth and soft feeling, excellent in sense of use such as powdering or the like, difficult to cause cracking and useful as makeup cosmetics such as foundation, face powder, rouge, or the like by adjusting hardness, porosity and impact resistant value to have specific respective values. SOLUTION: The compressed powdery cosmetics have &lt;=75 hardness measured with Asker C1L rubber hardness tester, &gt;=0.4 porosity and &gt;=5 impact resistant value (over the times of which irregularity brings about when repeatedly dropping a molded product from 50 cm height on a lauan plywood having 25 mm thickness). The cosmetics are pref. prepared by mixing powder (pref. mica treated with silicone), a film-forming polymer having &lt;=200 kg/cm2 elastic modulus [e.g. poly(N-acylalkyleneimine)-modified silicone or the like] and a volatile solvent (e.g. water) and then by evaporating the volatile solvent to conduct compression.
FIELD: veterinary virology, biotechnology. SUBSTANCE: method involves preparing virus-containing material from the strain &#34;VNIVIP-DEP&#34; and the following purification of virus-containing material is carried out by method of molecular-sieve chromatography on macroporous glass with pore diameter corresponding to diameter of virus virion to be purified. The best result is obtained using macroporous glass modified with polyvinylpyrrolidone with pore diameter 1200  , not less. Then method involves adsorption of highly purified antigen in the protein concentration 5-10 mcg/0.1 cm 3 , not less. Antispecies immunoperoxidase conjugate raised against to chicken IgG is used as conjugate. In carrying out spectrophotometric recording results in assay of final titer of sample to be analyzed by a single dilution 1:100 the following equation is used: lg titer = 2.19 x (LgS/P) + 3.59 where S/P = (S-NKx)/(PKx + NKx); S means value of optical density of analyzed serum; P means value of optical density of positive control; NKx means an average value of optical density of negative control; PKx means an average value of optical density of positive control. Invention can be used for determination of specific antibodies raised to chicken tenosynovitis reovirus by method of immunoenzyme analysis. EFFECT: enhanced sensitivity and specificity of analysis. 4 cl, 2 tbl
PURPOSE:A powder of man&#39;s hair, which is obtained by crusing hairs at a temperature lower than a prescribed one, is include as an effective component to give the titled composition that is high-safety, because it causes no skin allergy, makes white hair parts inconspicuous, increase the moisture retention of the hair and gives flexibility and gloss to the hair. CONSTITUTION:Man&#39;s hair that has been cut off and dumped from barber&#39;s shops is washed with water to remove foreign substances, treated with a detergent to effect defatting, when necessary, desinfected with an aqueous solutio of benzalkonium chloride and dried. Then, the man&#39;s hair is crushed at a low temperature of lower than -100 deg.C, preferably at -120--140 deg.C. As the cooling medium, is used liquid nitrogen that is produced advantageously by utilizing the coldness of liquefied natural gas (LNG) to cool air. The objective hair-dressin composition includes a fine powder of man&#39;s hair with particle sizes of less than 200mesh (74mum). Further, keratin extracted from the fine powder of man&#39;s hair may be added to a hair- dressing composition.